Wesley Self Archives
Jan. 5, 2023—The ACTIV-4 Host Tissue clinical trial platform, which is designed to investigate therapies targeting the host tissue response to COVID-19 to mitigate lung injury, is now being expanded internationally.
Dec. 16, 2022—The new bivalent mRNA COVID-19 booster vaccines that began being used in September are beneficial in preventing COVID-19-associated hospitalization in persons 65 and over.
Dec. 16, 2022—by Bill Snyder Gordon Bernard, MD, a leader in clinical and translational medicine at Vanderbilt University Medical Center for more than 40 years, will step aside from his institutional leadership roles in July 2023 to focus more on his research interests and allow a new generation of leaders to take center stage. Bernard, the Melinda...
Sep. 22, 2022—Wesley Self, MD, MPH, a physician-scientist at Vanderbilt University Medical Center, has been named co-principal investigator (co-PI) of Vanderbilt’s Clinical and Translational Science Award (CTSA).
Jul. 7, 2022—A Vanderbilt clinical trial shows that convalescent plasma, widely given to severely ill patients hospitalized with COVID-19 during the pandemic, does not improve their ability to survive or recover
Apr. 13, 2022—Additional booster doses of vaccine against COVID-19 are particularly important for those who are immunosuppressed, namely those who have had solid organ transplants, a new study shows.
Feb. 9, 2022—Vanderbilt research shows that two doses of an mRNA COVID-19 vaccine result in lower effectiveness for preventing hospitalization for the omicron variant than previous variants. However, importantly, a third (“booster”) vaccine dose significantly improves protection against omicron hospitalization up to 86%.
Jan. 6, 2022—by Nancy Humphrey Investigators at Vanderbilt University Medical Center have received a $10.7 million research award from the Centers for Disease Control and Prevention (CDC) to continue the IVY Research Network, originally created in 2019 to look at how well flu vaccines work at preventing severe flu illness, and expanded in 2021 to enroll patients...
Jul. 26, 2021—Vanderbilt University Medical Center researchers, supported by the National Institutes of Health (NIH), are leading a nationwide clinical trial to explore the safety and effectiveness of a group of novel drugs designed to protect patients hospitalized with COVID-19 at high risk of poor outcomes.
Mar. 2, 2021—As the Federal Drug Administration (FDA) considers adding a third COVID-19 vaccine to the rollout, a multicenter study led by Vanderbilt University Medical Center will evaluate how effective the vaccines are in preventing hospitalization from COVID-19.
Feb. 5, 2021—Treatment with convalescent plasma vastly improved the survival rate of patients hospitalized for COVID-19 who also had hematologic malignances that compromise the immune system, according to new data released by the COVID-19 and Cancer Consortium (CCC19).
Nov. 9, 2020—Findings from a national study published Nov. 9 in the Journal of the American Medical Association (JAMA) “do not support” the use of hydroxychloroquine for the treatment of adult patients hospitalized with COVID-19, the report concludes.